RxDoctor Payments Data

Sarah Lynch, APRN

Psychiatric/Mental Health · Orange Park, FLNPI 1669013595

Payments from drug & device makers

$5,204in general payments, 2019–2025

Across 278 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$808
  • Teva Pharmaceuticals USA, Inc.$629
  • Otsuka America Pharmaceutical, Inc.$463
  • Johnson & Johnson$404
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
  • Sunovion Pharmaceuticals Inc.$372
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,188100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,204 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$27,616
Medicare patients
65
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole13$34,368
Invega SustennaPaliperidone Palmitate13$28,115
Lurasidone Hcl43$24,627
VraylarCariprazine Hcl12$16,670
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$3,637
Aripiprazole47$2,654
Bupropion XlBupropion Hcl82$2,340
Olanzapine61$2,223
Quetiapine Fumarate97$1,808
Buspirone Hcl100$1,491
Duloxetine Hcl34$1,129
Lamotrigine69$1,105
Clonazepam98$950
Trazodone Hcl78$889
Mirtazapine55$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$463$34,36813 claims
Johnson & JohnsonInvega Sustenna$404$28,11513 claims
AbbVieVraylar$808$16,67012 claims
Almatica Pharma LLCSertraline Hcl$64$39846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →